1. Orasure Technologies is a Pennsylvania-based developer of diagnostic tests for HIV and hepatitis C antibodies, solutions for testing abusive drugs and cryosurgical products. As The Motley Fool notes, the company has yet to meet a profit but they are improving financially and recently formed a partnership with AbbVie. They are also developing a test for Ebola.
2. Orexigen Therapeutics is a La Jolla, Calif.,-based developer of prescription drugs to treat obesity and it won regulatory approval for a weight-loss drug, Contrave, last September. Orexigen is losing money but recently secured European regulatory approval and data from its Light Study claimed Contrave can improve cardiovascular outcomes. “The average one-year price target for Orexigen reflects an increase of nearly 70 percent above the current price of the stock,” reports The Motley Fool.
3. Pacific Biosciences of California is a Menlo Park, Calif.,-based genetic sequencing leader who have yet to see profits, but according to The Motley Fool,they are currently seeing revenue growth — from less than $2 million in 2010 to over $60 million last year. They also have the possibility of being bought by Roche.
More articles on ASC issues:
136 ASC women leaders to know
U.S. health spending sees acceleration: 5 key findings
4 key statistics on how physicians are being paid
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
